Abstract：
OBJECTIVE: Ceftaroline, a broad-spectrum cephalosporin, has activity against Gram-positive and several Gram-negative bacteria (GNB). This study aimed to evaluate the antimicrobial activity of ceftaroline and comparators against isolates causing skin and soft tissue infections (SSTIs) and respiratory tract infections (RTIs) collected in Latin America (LATAM) in 2016-2020 as part of the Antimicrobial Testing Leadership and Surveillance program (ATLAS).
METHODS: Minimum inhibitory concentrations were determined using both Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria.
RESULTS: Ceftaroline demonstrated potent activity against methicillin-susceptible Staphylococcus aureus (CLSI/EUCAST: MIC90 0.25 mg/L; susceptibility 100%), whereas activity against methicillin-resistant S. aureus varied for SSTIs (MIC90 1 mg/L; susceptibility 92.5%) and RTIs isolates (MIC90 2 mg/L; susceptibility 72.9%) isolates. For Streptococcus pneumoniae, particularly penicillin-resistant isolates commonly causing respiratory infections, high ceftaroline activity (MIC90 0.25 mg/L; susceptibility 100%/98.4%) was noted. All isolates of β-hemolytic streptococci were susceptible to ceftaroline (S. agalactiae: MIC90 0.03 mg/L [SSTIs]; MIC90 0.015 mg/L (RTIs); susceptibility 100%; S. pyogenes: MIC90 0.008 mg/L; susceptibility 100%). Ceftaroline was highly active against Haemophilus influenzae, including β-lactamase positive isolates (MIC90 0.06 mg/L; susceptibility 100%/85.7%). Ceftaroline demonstrated high activity against non-ESBL-producing GNB (E. coli: MIC90 0.5 mg/L, susceptibility 91.9%; K. pneumoniae: MIC90 0.25 mg/L, susceptibility 95.1%; K. oxytoca, MIC90 0.5 mg/L; susceptibility 95.7%).
CONCLUSIONS: Ceftaroline was active against the recent collection of bacterial pathogens commonly causing SSTIs and RTIs in LATAM. Local and regional surveillance of antimicrobial resistance patterns are crucial to understand evolving resistance and guide treatment management.
METHODS: Minimum inhibitory concentrations were determined using both Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria.
RESULTS: Ceftaroline demonstrated potent activity against methicillin-susceptible Staphylococcus aureus (CLSI/EUCAST: MIC90 0.25 mg/L; susceptibility 100%), whereas activity against methicillin-resistant S. aureus varied for SSTIs (MIC90 1 mg/L; susceptibility 92.5%) and RTIs isolates (MIC90 2 mg/L; susceptibility 72.9%) isolates. For Streptococcus pneumoniae, particularly penicillin-resistant isolates commonly causing respiratory infections, high ceftaroline activity (MIC90 0.25 mg/L; susceptibility 100%/98.4%) was noted. All isolates of β-hemolytic streptococci were susceptible to ceftaroline (S. agalactiae: MIC90 0.03 mg/L [SSTIs]; MIC90 0.015 mg/L (RTIs); susceptibility 100%; S. pyogenes: MIC90 0.008 mg/L; susceptibility 100%). Ceftaroline was highly active against Haemophilus influenzae, including β-lactamase positive isolates (MIC90 0.06 mg/L; susceptibility 100%/85.7%). Ceftaroline demonstrated high activity against non-ESBL-producing GNB (E. coli: MIC90 0.5 mg/L, susceptibility 91.9%; K. pneumoniae: MIC90 0.25 mg/L, susceptibility 95.1%; K. oxytoca, MIC90 0.5 mg/L; susceptibility 95.7%).
CONCLUSIONS: Ceftaroline was active against the recent collection of bacterial pathogens commonly causing SSTIs and RTIs in LATAM. Local and regional surveillance of antimicrobial resistance patterns are crucial to understand evolving resistance and guide treatment management.
摘要：
目标：头孢洛林，广谱头孢菌素具有抗革兰氏阳性和几种革兰氏阴性细菌(GNB)的活性。这项研究旨在评估头孢洛林和比较剂对2016-2020年在拉丁美洲（LATAM）收集的引起皮肤和软组织感染（STTI）和呼吸道感染（RTIs）的分离株的抗菌活性，作为抗菌测试领导和监测计划（ATLAS）的一部分。
方法：使用临床和实验室标准协会（CLSI）和欧洲抗菌药物敏感性测试委员会（EUCAST）标准确定最小抑制浓度。
结果：头孢洛林对甲氧西林敏感的金黄色葡萄球菌表现出有效的活性（CLSI/EUCAST：MIC900.25mg/L；敏感性100％），而针对耐甲氧西林金黄色葡萄球菌的活性因SSTIs（MIC901mg/L；敏感性92.5％）和RTIs分离株（MIC902mg/L；敏感性72.9％）而有所不同。对于肺炎链球菌，特别是青霉素耐药菌株通常会引起呼吸道感染，发现头孢洛林活性高(MIC900.25mg/L;敏感性100%/98.4%)。所有分离的β-溶血性链球菌对头孢洛林敏感[。无乳：MIC900.03mg/L（SSTIs）；MIC900.015mg/L（RTIs）；敏感性100％；化脓性链球菌：MIC900.008mg/L；敏感性100％）。头孢洛林对包括β-内酰胺酶阳性的流感嗜血杆菌具有较高的活性（MIC900.06mg/L；敏感性为100％/85.7％）。头孢洛林对不产生ESBL的GNB表现出高活性(E.大肠杆菌：MIC900.5mg/L，敏感性91.9%；肺炎克雷伯菌：MIC900.25mg/L，敏感性95.1%；氧化钾，MIC900.5mg/L；敏感性95.7%）。
结论：头孢洛林对最近在LATAM中通常引起SSTI和RTIs的细菌病原体具有活性。对抗生素耐药性模式的本地和区域监测对于了解不断发展的耐药性和指导治疗管理至关重要。
方法：使用临床和实验室标准协会（CLSI）和欧洲抗菌药物敏感性测试委员会（EUCAST）标准确定最小抑制浓度。
结果：头孢洛林对甲氧西林敏感的金黄色葡萄球菌表现出有效的活性（CLSI/EUCAST：MIC900.25mg/L；敏感性100％），而针对耐甲氧西林金黄色葡萄球菌的活性因SSTIs（MIC901mg/L；敏感性92.5％）和RTIs分离株（MIC902mg/L；敏感性72.9％）而有所不同。对于肺炎链球菌，特别是青霉素耐药菌株通常会引起呼吸道感染，发现头孢洛林活性高(MIC900.25mg/L;敏感性100%/98.4%)。所有分离的β-溶血性链球菌对头孢洛林敏感[。无乳：MIC900.03mg/L（SSTIs）；MIC900.015mg/L（RTIs）；敏感性100％；化脓性链球菌：MIC900.008mg/L；敏感性100％）。头孢洛林对包括β-内酰胺酶阳性的流感嗜血杆菌具有较高的活性（MIC900.06mg/L；敏感性为100％/85.7％）。头孢洛林对不产生ESBL的GNB表现出高活性(E.大肠杆菌：MIC900.5mg/L，敏感性91.9%；肺炎克雷伯菌：MIC900.25mg/L，敏感性95.1%；氧化钾，MIC900.5mg/L；敏感性95.7%）。
结论：头孢洛林对最近在LATAM中通常引起SSTI和RTIs的细菌病原体具有活性。对抗生素耐药性模式的本地和区域监测对于了解不断发展的耐药性和指导治疗管理至关重要。
